EUVIMEDEUVIMED entdecken
Open Access

Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases

Kathryn R Tringale iD, Anna Skakodub iD, Jacklynn Egger, Jordan Eichholz, Yao Yu iD, Daniel Gomez, Andreas Rimner iD, Bob Li iD, Yoshiya Yamada, Jessica Wilcox, Nelson Moss iD, Brandon S Imber iD und 4 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Kathryn R Tringale und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Small cell lung cancer (SCLC) often metastasizes to the brain and has poor prognosis. SCLC subtypes distinguished by expressing transcriptional factors ASCL1 or NEUROD1 have been identified. This study investigates the impact of transcription factor–defined SCLC subtype on incidence and outcomes of brain metastases (BMs). METHODS Patients with SCLC with ASCL1 (A) and NEUROD1 (N) immunohistochemical expression status were identified and classified: (1) A+/N–, (2) A+/N+, (3) A–/N+, and (4) A–/N–. Cumulative incidence competing risk analyses were used to assess incidence of CNS progression. Cox proportional hazards models were used for multivariable analyses of overall survival (OS) and CNS progression-free survival (CNS-PFS). RESULTS Of 164 patients, most were either A+/N– or A+/N+ (n = 62, n = 63, respectively). BMs were present at diagnosis in 24 patients (15%). Among them, the 12-month cumulative incidence of subsequent CNS progression was numerically highest for A+/N– (50% [95% CI, 10.5 to 74.7]; P = .47). Among those BM-free at diagnosis, the 12-month cumulative incidence of CNS progression was numerically the highest for A+/N– (16% [95% CI, 7.5 to 27.9]) and A–/N+ (9.1% [95% CI, 0.0 to 34.8]; P = .20). Both subtypes, A+/N– and A–/N+, had worse OS compared with A+/N+ (A+/N–: hazard ratio [HR], 1.62 [95% CI, 1.01 to 2.51]; P < .05; A–/N+: HR, 3.02 [95% CI, 1.35 to 6.76]; P = .007). Excellent response rates (28, 65% CR/PR) across subtypes were seen in patients who had CNS-directed radiotherapy versus systemic therapy alone (9, 36% CR/PR). CONCLUSION To our knowledge, this report is the first to investigate CNS-specific outcomes based on transcription factor subtypes in patients with SCLC. BM-free patients at diagnosis with A+/N– or A–/N+ subtypes had worse outcomes compared with those with transcriptional factor coexpression. Further investigation into the mechanisms and implications of SCLC subtyping on CNS-specific outcomes is warranted to ultimately guide personalized care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsBrain NeoplasmsHumansMaleFemaleMiddle AgedPrognosisAgedBasic Helix-Loop-Helix ProteinsAdultAged, 80 and overCentral Nervous System NeoplasmsRetrospective Studies

Substanzen

Basic Helix-Loop-Helix ProteinsASCL1 protein, humanNEUROD1 protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, CA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Biomarker Development Program, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Kathryn R Tringale, Anna Skakodub, Yao Yu, Andreas Rimner, Bob Li, Nelson Moss, Brandon S Imber, Natasha Rekhtman, Marina K Baine, Charles M Rudin, Luke R G Pike

Förderung

  • NCI NIH HHS

Zitieren

APA

Tringale, K. R., Skakodub, A., Egger, J., Eichholz, J., Yu, Y., Gomez, D., Rimner, A., Li, B., Yamada, Y., Wilcox, J., Moss, N., Imber, B. S., Rekhtman, N., Baine, M. K., Rudin, C. M., & Pike, L. R. G. (2024). Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases. JCO Precision Oncology. https://doi.org/10.1200/po.23.00470

Vancouver

Tringale KR, Skakodub A, Egger J, Eichholz J, Yu Y, Gomez D, et al. Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases. JCO Precision Oncology. 2024. doi:10.1200/po.23.00470

BibTeX
@article{Tringale2024,
  author = {Tringale, Kathryn R and Skakodub, Anna and Egger, Jacklynn and Eichholz, Jordan and Yu, Yao and Gomez, Daniel and Rimner, Andreas and Li, Bob and Yamada, Yoshiya and Wilcox, Jessica and Moss, Nelson and Imber, Brandon S and Rekhtman, Natasha and Baine, Marina K and Rudin, Charles M and Pike, Luke R G},
  title = {Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00470}
}
Kostenlos starten →